UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 478

Sortiert nach

Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer

Annals of oncology, 2022-03, Vol.33 (3), p.350-352

2022

Volltextzugriff (PDF)

Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial

Neurology, 2010-03, Vol.74 (9), p.762

2010

Volltextzugriff (PDF)

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

Annals of oncology, 2011-10, Vol.22 (10), p.2277-2285

2011

Volltextzugriff (PDF)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer

Annals of oncology, 2022-05, Vol.33 (5), p.563-565

2022

Volltextzugriff (PDF)

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

Annals of oncology, 2012-03, Vol.23 (3), p.695-700

2012

Volltextzugriff (PDF)

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine

Annals of oncology, 2011-03, Vol.22 (3), p.625-630

2011

Volltextzugriff (PDF)

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

British journal of cancer, 2010-11, Vol.103 (10), p.1542-1547

2010

Volltextzugriff (PDF)

Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer

Annals of oncology, 2017-11, Vol.28 (11), p.2896-2898

2017

Volltextzugriff (PDF)

Real-life utilization of genomic testing for invasive breast cancer patients in Italy and France reduces chemotherapy recommendations

Annals of oncology, 2018-10, Vol.29, p.viii61-viii61

2018

Volltextzugriff (PDF)

The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial

Annals of oncology, 2019-05, Vol.30, p.iii28-iii28

2019

Volltextzugriff (PDF)

Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials

Annals of oncology, 2018-10, Vol.29, p.viii111-viii111

2018

Volltextzugriff (PDF)

Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy

Annals of oncology, 2018-10, Vol.29, p.viii311-viii312

2018

Volltextzugriff (PDF)

Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy

Journal of clinical oncology, 2003-03, Vol.21 (5), p.927-931

2003

Volltextzugriff (PDF)

Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab

Annals of oncology, 2018-10, Vol.29, p.viii105-viii105

2018

Volltextzugriff (PDF)

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

Expert review of clinical pharmacology, 2021-02, Vol.14 (2), p.261-268

2021

Volltextzugriff (PDF)

Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2018-10, Vol.29, p.viii314-viii314

2018

Volltextzugriff (PDF)

Should we consider altering our patterns of care for elderly sarcoma patients?

Annals of oncology, 2018-10, Vol.29, p.viii593-viii593

2018

Volltextzugriff (PDF)

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

Annals of oncology, 2012-06, Vol.23 (6), p.1436-1441

2012

Volltextzugriff (PDF)

Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi27

2017

Volltextzugriff (PDF)

Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial

Annals of oncology, 2017-10, Vol.28, p.vi1-vi1

2017

Volltextzugriff (PDF)

Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM)

Annals of oncology, 2017-10, Vol.28, p.vi59-vi59

2017

Volltextzugriff (PDF)

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

Annals of oncology, 2017-10, Vol.28, p.vi25-vi25

2017

Volltextzugriff (PDF)

A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi25

2017

Volltextzugriff (PDF)

533 (PB-166) - Real-Life Utilization of the 21-Gene Assay in Italian Clinical Practice

European journal of cancer (1990), 2018-04, Vol.92, p.S156-S157

2018

Volltextzugriff (PDF)

Real-Life Utilization of the 21-Gene Assay in Italian Clinical Practice

European journal of cancer (1990), 2018-04, Vol.92, p.S156-S157

2018

Volltextzugriff (PDF)

1 – 25 von 478

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(456)
Mit Volltextzugriff
(448)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(201)
Life Sciences & Biomedicine
(196)
Humans
(188)
Oncology
(164)
Female
(143)
Middle Aged
(120)
Aged
(110)
Adult
(101)
Biological And Medical Sciences
(97)
Medical Sciences
(96)
Male
(89)
Pharmacology. Drug Treatments
(67)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(60)
Antineoplastic Agents
(50)
Breast Neoplasms - Drug Therapy
(49)
Chemotherapy
(46)
Tumors
(46)
Treatment Outcome
(43)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(42)
Breast Neoplasms - Pathology
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer

Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer

Real-life utilization of genomic testing for invasive breast cancer patients in Italy and France reduces chemotherapy recommendations

The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial

Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials

Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy

Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy

Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)

Should we consider altering our patterns of care for elderly sarcoma patients?

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer

Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis

Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial

Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM)

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer

533 (PB-166) - Real-Life Utilization of the 21-Gene Assay in Italian Clinical Practice

Real-Life Utilization of the 21-Gene Assay in Italian Clinical Practice

Suchergebnisse filtern